This content is for members only
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 for its lymphoma drug candidate Selinexor, noting patients who experienced a complete or partial response in a 125-patient trial had a median overall survival rate of 29.7 months. Previously published […]
This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only
Because FDA marketing clearance to sell a drug or device in the US remains the brass ring for medical manufacturers around the world, companies consistently invested in US trials in spite of rising costs. By 2016, however, more manufacturers were […]